Doing harm reduction better: Syringe exchange in the United States

Addiction

Volumn 104, Issue 9, 2009, Pages 1441-1446

  Des Jarlais, Don C ^a   McKnight, Courtney ^a   Goldblatt, Cullen ^a   Purchase, David ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b N American Syringe Exchange Network   (United States)

Author keywords

Harm reduction; HIV; Injecting drug use; Substance use; Syringe exchange; United States

Indexed keywords

NALOXONE;

CONTROLLED STUDY; DRUG OVERDOSE; HARM REDUCTION; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; REVIEW; SUBSTANCE ABUSE; SYRINGE; UNITED STATES;

HARM REDUCTION; HUMANS; NEEDLE-EXCHANGE PROGRAMS; STATE GOVERNMENT; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 68249124121     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02465.x     Document Type: Review

References (14)

1. Des Jarlais D. C., Friedman S. R. Intravenous cocaine, crack, and HIV infection. JAMA 1998 259 : 1945 50.
2. Golub A., Johnson B. D. The crack epidemic: empirical findings support a hypothesized diffusion of innovation process. Soci-Econ Plann Sci 1996 30 : 221 31.
3. Anderson W. The New York needle trial: the politics of public health in the age of AIDS. Am J Public Health 1991 81 : 1506 17.
4. Santibanez S., Garfein R., Swartzendruber A., Purcell D. W., Paxton L. A., Greenberg A. E. Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. J Urban Health 2006 83 : 86 100.
5. Centers For Disease Control and Prevention. HIV diagnoses among injection drug users, 33 states. MMWR 2005 54 : 1149 53.
6. Strathdee S., Galai N., Safaeian M., Celentano D. D., Vlahov D., Johnson L. et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med 2001 161 : 1281 8.
7. Des Jarlais D. C., Perlis T., Arasteh K., Torian L. V., Beatrice S., Milliken J. et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health 2005 95 : 1439 44.
8. Tempalski B., Cooper H., Friedman S. R., Des Jarlais D. C., Brady J., Gostnell K. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy 2008 19 : S47 58.
9. Bluthenthal R., Ridgeway G., Schell T., Anderson R., Flynn N. M., Kral A. H. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction 2007 102 : 638 46.
10. Bluthenthal R., Anderson R., Flynn N., Kral A. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend 2007 89 : 214 22.
11. Des Jarlais D., Arasteh K., Perlis T., Hagan H., Abdul-Quader A., Heckathorn D. D. et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City: a new stage in a very large HIV epidemic. AIDS 2007 21 : 231 5.
12. Hagan H., Thiede H., Weiss N. S., Hopkins S. G., Duchin J. S., Alexander E. R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001 91 : 42 6.
13. Des Jarlais D. C., Hagan H., Perlis T., Arasteh K., Torian L. V., Beatrice S. et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005 19 : S20 25.
14. Brown v. Board of Education, 347 U.S. 483. 1954. Available at: http://caselaw.lp.findlaw.com/scripts/getcase.pl?court=US&vol=347&invol= 483 (accessed 25 September 2008).